You are here Home Resources and guidance Publications Meeting statements ACV meeting statement, meeting 51, 5 February 2025 Advisory Committee on Vaccines Published 11 March 2025 Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Section A: Premarket registration applicationsAt this meeting the committee provided advice on one application under evaluation by the TGA.Active ingredient (TRADENAME)SponsorTherapeutic areaApplication designationsApplication for a 'new indication', or additional therapeutic use, for an already approved vaccine (Application Type C)recombinant respiratory syncytial virus pre-fusion F protein(AREXVY)GlaxoSmithKline Australia Pty LtdFor the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV). The date of commencement of the evaluation of the application is available at Prescription medicines: Applications under evaluation.Further details of the ACV discussion and advice associated with items may be released within the Australian Public Assessment Reports (AusPAR).Section B: Post-market itemsThe ACV was not asked to provide advice on a post-market or safety issue.Further informationFor further information on the Advisory Committee on Vaccines, please visit Advisory Committee on Vaccines (ACV) or contact the ACV Secretary by email: ACV@health.gov.au. Outcome of Advisory Committee on Vaccines (ACV)
